ABVC
ABVC BioPharma, Inc.
There isn't enough reported data to score ABVC yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ABVC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ABVC's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ABVC PE Valuation
ABVC has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ABVC Forward outlook
There aren't enough analyst estimates for ABVC to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ABVC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$1.38 | +$2.02 |
| Q2 2024 | -$2.18 | +$1.50 |
| Q1 2024 | -$2.77 | +$0.83 |
| Q4 2023 | -$2.97 | +$2.03 |
| Q3 2023 | -$3.40 | +$3.35 |
| Q2 2023 | -$3.68 | +$2.67 |
| Q1 2023 | -$3.60 | +$2.95 |
| Q4 2022 | -$5.00 | +$0.05 |
ABVC has the stronger earnings trend. Trailing diluted EPS is down 114% for ABVC versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ABVC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $796K | +104% |
| Q4 2024 | $2K | -9.2% |
| Q3 2024 | $389.3K | +2351% |
| Q2 2024 | $117.1K | +1818% |
| Q1 2024 | $1.2K | -99% |
| Q4 2023 | $2.2K | -100% |
| Q3 2023 | $15.9K | -62% |
| Q2 2023 | $6.1K | -98% |
HIMS has the stronger quarterly revenue trend. Revenue is down 779% for ABVC versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -247% | -260 points |
| Q4 2024 | -16997% | +73609 points |
| Q3 2024 | 13% | +13579 points |
| Q2 2024 | -834% | +35078 points |
| Q1 2024 | -285841% | -284355 points |
| Q4 2023 | -90606% | -90074 points |
| Q3 2023 | -13566% | -4775 points |
| Q2 2023 | -35912% | -35257 points |
ABVC's operating margin was −247% last quarter, up 285595 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ABVC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$894.2K | -$354.4K |
| Q2 2025 | -$894.2K | +$119.9K |
| Q1 2025 | -$539.8K | -$66.7K |
| Q1 2024 | -$473.2K | +$1M |
| Q1 2023 | -$1.5M | +$1.6M |
| Q2 2022 | -$3.5M | -$2M |
| Q1 2022 | -$3.1M | -$1.7M |
| Q4 2021 | -$1.8M | +$1.4M |
ABVC has the stronger cash trend. Its trailing FCF is up 29% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ABVC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +598K shares |
| 1 year | +15% | +3.4M shares |
| 3 years | +706% | +23.3M shares |
| 5 years | +992% | +24.2M shares |
| Available history | +1423% | +24.9M shares |
ABVC has 27M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2021 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ABVC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ABVC Net Leverage
ABVC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ABVC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 51.7 | Neutral |
ABVC's weekly RSI is 43 (neutral) and its Stochastic is 52 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ABVC PE vs Healthcare Sector
ABVC has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ABVC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 4% below |
| 20 week MA | $1.07 | 10% below |
| 50 week MA | $1.36 | 29% below |
| 100 week MA | $1.60 | 40% below |
| 200 week MA | $2.06 | 53% below |
ABVC is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ABVC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.5 | $52.0 | +1% |
| 2021 | $52.0 | $37.7 | -27% |
| 2022 | $37.7 | $6.90 | -82% |
| 2023 | $6.90 | $1.16 | -83% |
| 2024 | $1.16 | $0.58 | -50% |
| 2025 | $0.58 | $2.43 | +319% |
| 2026 YTD | $2.43 | $0.96 | -60% |
ABVC's yearly returns have swung widely, from +319% in 2025 to −83% in 2023. It's down 60% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ABVC on returns for 2026, with the stronger performance.